SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Tower’s surge continues as valuation crosses $20 billion mark

Learning to manage the cloud without losing control

Cash-strapped AI chip startup Hailo sees valuation halved to under $500 million ahead of urgent IPO

Israeli drone factory hit by Iranian missile

Buzz

Most popular

Daily

Weekly

1

“Today is your last day”: Oracle’s mass layoffs unfold without warning

2

"Cyera is already the Wiz of data security. We want to be the Palo Alto Networks of data security"

3

Israel gas cutoff exposes deep energy divide between Jordan and Egypt

4

“We’re doing for identity what Wiz did for cloud”: Linx Security raises $50 million Series B

5

Iranian missile attack sparks fire and renews fears over Israel’s chemical hubs

NeuroKaire

3 stories about NeuroKaire

טליה כהן סולל ו דפנה לייפנפלד

Big Tech on the witness stand: Are algorithms responsible for the mental health crisis?

19.02.26|Dr. Talia Cohen-Solel and Dr. Daphna Laifenfeld

The most significant contribution of the ongoing trial may ultimately not be the verdict itself, but the shift in public discourse it has generated.

לייפנפלד )מימין( וכהן־סולל במשרדי NeuroKairs בתל אביב. "יכולנו לשבת כמו כל הסטארט־ אפים באחד ממגדלי ההייטק, אבל חשוב לנו לא להוציא כסף על מה שלא חובה"

The women turning a blood sample into a map of the depressed brain

27.11.25|Sophie Shulman

Tel Aviv-based NeuroKaire is using “brain-in-a-dish” models to personalize antidepressants, and is now shifting from years of research to full-scale commercialization in Israel and the U.S.

טליה כהן סולל ו דפנה לייפנפלד

Israeli startup NeuroKaire launches world’s first blood test to personalize depression treatment

09.09.25|Maayan Cohen Rozen

BrightKaire uses AI and stem-cell technology to match patients with effective medications, potentially ending years of trial-and-error prescribing.